NAMI
KRYS icon

Nomura Asset Management International’s Krystal Biotech KRYS Stock Holding History

Nomura Asset Management International’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.7M Buy
12,642
+2,424
+24% +$724K 0.01% 867
2026
Q1 		$2.64M Buy
10,218
+627
+7% +$167K ﹤0.01% 915
2025
Q4 		$2.37M Buy
+9,591
New +$2.02M ﹤0.01% 967

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Nomura Asset Management International's KRYS Position: Q2 2026 in Review

Nomura Asset Management International increased its Krystal Biotech (KRYS) stake by 24% in Q2 2026, buying an estimated $724K and bringing the position to 12,642 shares worth $4.7M. The position accounts for 0.01% of the portfolio, ranked #867.

Nomura Asset Management International first reported a position in KRYS in Q4 2025 and has held it in 3 quarters since. 422 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Nomura Asset Management International held 12,642 shares of Krystal Biotech worth $4.7M as of Q2 2026.
  • Nomura Asset Management International bought 2,424 Krystal Biotech shares in Q2 2026, an estimated $724K.
  • Krystal Biotech made up 0.01% of Nomura Asset Management International's portfolio in Q2 2026, its #867 holding.
  • Nomura Asset Management International first reported a position in Krystal Biotech in Q4 2025 and has held it in 3 quarters since.
  • 422 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Nomura Asset Management International's 13F filing for Q2 2026, filed 14 Aug 2026.